MS drug controversy, adoption outcomes in Sweden, and the multi-factorial reality of Alzheimer’s
About this episode
The episode discusses the FDA re-evaluation of the MS drug Ocrelizumab, adoption outcomes in Sweden, and challenges in understanding Alzheimer's disease.
A blockbuster MS drug undergoes FDA re-evaluation. We explore the story of Ocrelizumab, a treatment for primary progressive multiple sclerosis, following a patient petition that highlighted internal disagreements among agency reviewers regarding its efficacy. We look to Sweden, where new research involving sibling pairs separated by adoption investigates how early-life environments shape long-term health and social outcomes. Finally, we revisit the dominant medical narrative on Alzheimer’s disease. Why is it so difficult to move towards comprehensive treatments? Has the focus on amyloid plaques hindered our understanding of other critical factors like vascular health and social inequality? Peter Doshi is a senior editor at The BMJ and an associate professor of pharmaceutical health services research at the University of Maryland. Erik Peterson is an associate professor at the Karolinska Institute in Stockholm, specializing in psychiatric epidemiology and adoption studies. Carol Brayne is a professor emerita of public health medicine at the University of Cambridge and a leading expert in the epidemiology of dementia. Reading List: Multiple sclerosis: Could Roche's bestselling drug…
More episodes of Medicine and Science from The BMJ
- The Trump administration is an international health emergency
- The 15th strike, and bringing compassion back to A&E
- The unchecked rise of shisha tobacco cafes, and making breastfeeding stick
- New Covid inquiry findings with Dr Kevin Fong, and invasive cosmetic procedures
- How the war in Iran will disrupt medical supplies around the world
- Is the NHS in danger of making misinformation worse?
Explore listener stats, chart rankings, contacts and more on the Medicine and Science from The BMJ podcast page.